Table 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer
收藏数据链接：
官方服务：
资源简介：
Summary of TEAEs (>15%) by preferred term and maximum CTCAE grade in descending frequency order (treatment-related, all cycles)—safety analysis set parts 1 and 2 (N = 151).
创建时间：
2025-07-15
